Regulatory perspectives on post-market evidence generation schemes for high-risk medical devices: a systematic review
Metadata
Show full item recordAuthor
Aranda, Jesús; Dobrzynska, Agnieszka; Rosario-Lozano, Maria Piedad; Rejón Parrilla, Juan Carlos; Epstein, David Mark; Blasco Amaro, Juan AntonioEditorial
Taylor & Francis group
Materia
High-risk medical devices market approval certificates of conformity
Date
2024-12-01Referencia bibliográfica
Aranda, J. et. al. Expert Review of Pharmacoeconomics & Outcomes Research, 1–15. [https://doi.org/10.1080/14737167.2024.2431234]
Sponsorship
H2020-SC1-BHC -2018-2020/H2020-SC1-2020-Single-Stage-RTD under grant agreement number 965246Abstract
Introduction: The new European Medical Device Regulation has raised the bar for the clinical evaluation of
medical devices to gain marketing authorization by Notified Bodies (NBs) regarding certificates of conformity
in Europe. Restrictions applied for High-risk medical devices (HRMD) may require further evidence
generation. Some other jurisdictions apply similar schemes that may be useful to the European Union. This
systematic review focused on extracting lessons from similar schemes worldwide to the European context.
Methods: A systematic review of peer-reviewed and gray literature was performed based on ‘Device
approval’ and ‘conditional approval’ keywords. Databases such as Medline, Embase, and WoS retrieved
documents assessed with the AMSTAR-2 checklist. A descriptive and narrative analysis was conducted
detailed in CRD42023431233 – PROSPERO.
Results: We obtained eight documents where conditional approvals for High-risk medical devices in the
United States of America, China, and Canada were subject to generate further evidence. In Europe, NBs
impose restrictions or limitations to certificates of conformity instead.
Conclusion: Further development of policies, supporting access to HRMD subject to further evidence
generation, would help Europe in further defining the appropriate situations for the application of determined
regulatory routes, to enhance access to HRMD with promising evidence and further evidence development.
Registration: PROSPERO (CRD42023431233).